Summary & Overview
HCPCS Q4431: PMA Skin Substitute Product, Add-On
HCPCS Level II code Q4431 denotes a PMA (premarket approval) skin substitute product billed as an adjunct to a primary procedure. Skin substitutes are used in surgical and wound-care settings to promote tissue repair and closure; as an add-on supply code, Q4431 captures the use of a regulated biologic or synthetic graft product that has received special regulatory clearance. Nationally, accurate coding of add-on skin substitute products affects clinical documentation, hospital and clinic supply accounting, and payer coverage determinations.
Key payers commonly referenced in coverage and payment discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of the code’s clinical context, typical sites of service, and payer landscape. The publication outlines common billing considerations, documentation expectations tied to adjunctive skin substitute use, and where to look for payer-specific coverage and reimbursement guidance.
This summary is intended to provide a clear, national-level overview of what Q4431 represents, why it is billed separately from primary procedures, and what readers should expect when reviewing benchmarks, policy updates, and clinical coding guidance related to add-on skin substitute products.
Billing Code Overview
HCPCS Level II code Q4431 describes a PMA skin substitute product, not otherwise specified, billed in addition to a primary procedure. The service type is a skin substitute application or implantation used to support wound closure and tissue repair. The typical site of service is inpatient or outpatient surgical settings, wound care clinics, or other procedural environments where skin substitutes are applied.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a non-healing full-thickness skin loss (chronic wound, diabetic foot ulcer, venous leg ulcer, or pressure ulcer) after initial debridement and wound bed preparation in an outpatient wound clinic or hospital-based wound center. The wound care specialist (podiatrist, plastic surgeon, or wound care physician) assesses the wound, performs sharp debridement and hemostasis, measures wound dimensions, and applies a point-of-care or pharmacy-supplied placental membrane allograft (PMA) skin substitute product as an adjunct to standard wound management. The application may occur in an ambulatory surgery center, hospital outpatient department, wound clinic, or bedside inpatient setting. Follow-up visits evaluate graft take, infection control, dressing changes, and documentation of serial wound measurements to support medical necessity for subsequent applications of the skin substitute.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a distinct E/M visit is performed on the same day as the PMA application and properly documented |
59 | Distinct procedural service |